PDS Biotechnology director granted 54,876 stock options

Iliev Ilian reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Iliev Ilian reported acquisition or exercise transactions in this Form 4 filing.

PDS Biotechnology Corp director Ilian Iliev received a grant of 54,876 employee stock options on January 12, 2026. These options were awarded at no cost as an equity incentive and will vest in full on the first anniversary of the grant date, provided he continues serving as a director.

Insider Trade Summary

Grant/Award: 54,876 shares

Grant/Award 1 txn

Insider Iliev Ilian

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	54,876	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 54,876 contracts (Direct)

Footnotes (1)

1. F1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PDS Biotechnology Corp (PDSB) report for Ilian Iliev?

PDS Biotechnology Corp reported that director Ilian Iliev received a grant of 54,876 employee stock options on January 12, 2026. The options were awarded as compensation and represent the right to buy company shares in the future, subject to vesting conditions.

How many stock options were granted to PDSB director Ilian Iliev in this Form 4?

Ilian Iliev was granted 54,876 employee stock options. These options were reported as a derivative security award and give him the right to purchase PDS Biotechnology Corp shares after they vest, assuming he satisfies the required continued service condition as a director.

When do Ilian Iliev’s PDS Biotechnology stock options vest?

The stock options granted to Ilian Iliev will vest in full on the first anniversary of the January 12, 2026 grant date. Vesting is contingent on his continued service to PDS Biotechnology Corp as a director through that one-year vesting date, according to the filing footnote.

What is the nature of the Form 4 transaction reported for PDSB’s Ilian Iliev?

The Form 4 shows an acquisition coded as a grant or award of derivative securities. Specifically, Ilian Iliev received 54,876 employee stock options as director compensation, rather than buying shares on the open market, with all options subject to future vesting conditions.

Does the PDSB Form 4 indicate any sale of shares by Ilian Iliev?

The Form 4 does not report any sale of PDS Biotechnology Corp shares by Ilian Iliev. It only discloses an acquisition in the form of a stock option grant, reflecting an increase in his potential future ownership if the options vest and are exercised.

What ongoing service requirement is tied to Ilian Iliev’s PDS Biotechnology option grant?

The options will vest only if Ilian Iliev continues serving as a director of PDS Biotechnology Corp through the first anniversary of the January 12, 2026 grant date. If he does not remain in that role through the vesting date, the options may not become exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:47 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Iliev Ilian

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		54,876		(1)	01/12/2036	Common Stock	54,876	$0	54,876	D

Explanation of Responses:

1. The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.

	/s/ Spencer Brown, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.